Immatics NVIMTX +1.80%60 EBITDA Margin % is -719.59% as of Mar. 2026. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 945 Biotechnology companies, Immatics NV ranks worse than 72.06% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Immatics NV's EBITDA for the
three
months ended in Mar. 2026 was $-63.32 Mil. Immatics NV's Revenue for the
three
months ended in Mar. 2026 was $8.80 Mil. Therefore, Immatics NV's EBITDA margin for the quarter that ended in Mar. 2026 was -719.59%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Immatics NV EBITDA Margin % Related Terms
Immatics NV EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Immatics NV's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMTX vs INVA, PGEN, VIR: EBITDA Margin % Comparison
For the Biotechnology subindustry, Immatics NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Immatics NV's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immatics NV (IMTX) has a EBITDA Margin % of -719.59% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Immatics NV and its competitors. According to the industry distribution chart, Immatics NV ranks #681 out of 945 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Immatics NV's EBITDA Margin % too high?
Immatics NV's current EBITDA Margin % is -719.59%. Based on the distribution chart, Immatics NV ranks #681 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's EBITDA Margin % compare to INVA and PGEN?
According to the Biotechnology industry distribution chart, Immatics NV ranks #681 out of 945 companies for EBITDA Margin %. This places Immatics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Immatics NV and its competitors. Immatics NV's current EBITDA Margin % is -719.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.57, compared to a current price of $10.20 — trading 185.7% above its estimated fair value. The current EBITDA Margin % is -719.59%. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Immatics NV (IMTX), the current EBITDA Margin % is -719.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $10.20 is trading 185.7% above its estimated GF Value™ of $3.57.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
EBITDA Margin %: -719.59%
GF Value™: $3.57 vs. price of $10.20 (185.7% above fair value)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score
Get the complete analysis for IMTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
